Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN

This study is testing a CAR-NK cell therapy — a type of immunotherapy where natural killer (NK) immune cells are engineered to attack cancer cells with a marker called CD123 — for people with acute myeloid leukemia (AML) or a rare blood cancer called BPDCN that has come back or stopped responding to treatment. **You may be eligible if...** - You are between 18 and 75 years old - Your cancer cells test positive for CD123 - You have been diagnosed with relapsed or refractory AML or BPDCN - You have previously been treated with standard chemotherapy or stem cell transplant and your cancer has returned or not responded **You may NOT be eligible if...** - Your cancer is CD123-negative - You have active serious infections (including uncontrolled HIV, hepatitis B, or C) - You have severe organ problems (heart, lungs, liver, kidneys) - You are pregnant or breastfeeding - You have recently had certain prior therapies that exclude you Talk to your doctor to see if this trial is right for you.